MA42130A - Combinaisons d'opioïdes et de n-acyléthanolamines - Google Patents

Combinaisons d'opioïdes et de n-acyléthanolamines

Info

Publication number
MA42130A
MA42130A MA042130A MA42130A MA42130A MA 42130 A MA42130 A MA 42130A MA 042130 A MA042130 A MA 042130A MA 42130 A MA42130 A MA 42130A MA 42130 A MA42130 A MA 42130A
Authority
MA
Morocco
Prior art keywords
acylethanolamines
opioids
combinations
Prior art date
Application number
MA042130A
Other languages
English (en)
Inventor
Ephraim Brener
Elran Haber
Ascher Shmulewitz
Original Assignee
Therapix Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapix Biosciences Ltd filed Critical Therapix Biosciences Ltd
Publication of MA42130A publication Critical patent/MA42130A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
MA042130A 2015-05-21 2016-05-17 Combinaisons d'opioïdes et de n-acyléthanolamines MA42130A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562164618P 2015-05-21 2015-05-21

Publications (1)

Publication Number Publication Date
MA42130A true MA42130A (fr) 2018-03-28

Family

ID=57319619

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042130A MA42130A (fr) 2015-05-21 2016-05-17 Combinaisons d'opioïdes et de n-acyléthanolamines

Country Status (12)

Country Link
US (2) US20180116982A1 (fr)
EP (1) EP3297622B1 (fr)
JP (2) JP7244992B2 (fr)
CN (2) CN107613966A (fr)
AU (4) AU2016263292B2 (fr)
CA (1) CA2985305C (fr)
DK (1) DK3297622T3 (fr)
ES (1) ES2968345T3 (fr)
IL (3) IL305528B2 (fr)
MA (1) MA42130A (fr)
PL (1) PL3297622T3 (fr)
WO (1) WO2016185468A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201802129QA (en) 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
PH12018000227A1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
US20240116851A1 (en) * 2021-12-23 2024-04-11 Board Of Regents, The University Of Texas System Use of d9-methadone for postoperative pain relief

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014868B (zh) * 2008-04-28 2014-11-12 莫尼科贾夫西尔瓦诺21控股股份公司 含有棕榈酰乙醇酰胺和硬脂酰乙醇酰胺的药物制剂
AU2013230425B2 (en) 2012-03-05 2017-05-25 Dr.Reddy's Laboratories Ltd. Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists
WO2014190271A2 (fr) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Méthodes de traitement de symptômes de la dépression
HUE044915T2 (hu) * 2014-05-14 2019-11-28 Epitech Group S P A Palmitoiletanolamid alkalmazása opioidokkal kombinációban

Also Published As

Publication number Publication date
CA2985305A1 (fr) 2016-11-24
AU2016263292A1 (en) 2017-11-30
PL3297622T3 (pl) 2024-03-18
CA2985305C (fr) 2024-04-09
DK3297622T3 (da) 2024-01-22
IL305528B1 (en) 2025-09-01
JP7244992B2 (ja) 2023-03-23
AU2023251499B2 (en) 2025-09-25
AU2021204517B2 (en) 2023-07-27
AU2025279727A1 (en) 2026-01-15
IL305528A (en) 2023-10-01
IL255749A (en) 2018-01-31
EP3297622A4 (fr) 2019-01-02
CN107613966A (zh) 2018-01-19
WO2016185468A1 (fr) 2016-11-24
AU2021204517A1 (en) 2021-07-29
IL305528B2 (en) 2026-01-01
CN116808038A (zh) 2023-09-29
ES2968345T3 (es) 2024-05-09
JP2021138703A (ja) 2021-09-16
US20180116982A1 (en) 2018-05-03
AU2016263292B2 (en) 2021-04-01
AU2023251499A1 (en) 2023-11-09
IL322263A (en) 2025-09-01
EP3297622A1 (fr) 2018-03-28
US20210177779A1 (en) 2021-06-17
EP3297622B1 (fr) 2023-11-01
JP2018515547A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
IL259495A (en) Antibodies and methods for using them
IL254039A0 (en) Anti-pvrig antibodies and methods of use
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
PT3548033T (pt) Compostos e respectivos métodos de utilização
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
IL251972B (en) Analyzing and utilizing landscapes
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
EP3800791C0 (fr) Codeur et décodeur polaires activés par signature
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
EP4212536C0 (fr) Composés de benzoxazepine oxazolidinone et procédés d'utilisation
PT3215532T (pt) Anticorpos anti-tim3 e métodos de utilização
MA49715A (fr) Oligomères et conjugués d'oligomères
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
MA41997A (fr) Combinaisons de cannabinoïdes et de n-acyléthanolamines
PT3319612T (pt) Oxisteróis e métodos de utilização dos mesmos
IL270793A (en) Anti-HTRA1 antibodies and methods of using them
BR112016020889A2 (pt) variantes de hppd e métodos de uso
EP3534910A4 (fr) Procédés et agents thérapeutiques
EP3398262A4 (fr) Caractérisation et sélection de micro-routes
EP3417845A4 (fr) Composition de formation de alpha-gel et composition de alpha-gel
IL255749A (en) Combinations of opioids and n-acylethanolamines
EP3513304A4 (fr) Fourniture de contenus recommandés